COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Spectranetics Corporation (Nasdaq:SPNC) today announced that it has made a pre-IDE (Investigational Device Exemption) submission to the Food and Drug Administration regarding the use of laser ablation to treat in-stent restenosis (ISR) in the legs. ISR is caused by the re-growth of tissue within the stent, known as neointimal hyperplasia, which can lead to blockages in the affected leg artery.
